ELV·Elevance Health, Inc.
ELV|Analyst Targets
ELV|Company Info
ELV|Insider Trading
ELV|Fundamentals
ELV|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $4.69 | - | - |
| Q2'26 | $5.07 | $7.45 | +47.0% |
| Q1'26 | $6.29 | $12.58 | +99.9% |
| Q4'25 | $3.13 | $3.33 | +6.5% |
| Q3'25 | $4.94 | $6.03 | +22.0% |
| Q2'25 | $8.96 | $8.84 | -1.4% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $49.7B | - | - |
| Q2'26 | $49.2B | $49.8B | +1.3% |
| Q1'26 | $48.0B | $49.5B | +3.2% |
| Q4'25 | $50.3B | $49.3B | -2.0% |
| Q3'25 | - | $50.1B | - |
| Q2'25 | - | $49.4B | - |
ELV|Monthly Returns
Market Data
ELV Stock Snapshot
- Market cap
- 90.23B
- P/E ratio
- 18.2
- Day range
- $420.99 – $433.89
- News sentiment
- 69/100 · Bullish
- Analyst target
- $451.71 (+6.0%)
- Consensus
- Buy · 31 analysts
The signal on ELV is bullish: price action is confirming the underlying trend, not fighting it. In Healthcare, names this size usually take direction from sector flows before company-level news.
Reverse DCF
What growth is priced into ELV?
At today's price, Elevance Health, Inc. needs to grow free cash flow about 12.7% a year for the next 10 years to justify its valuation at a 6.83% cost of capital. Over its actual history it has compounded free cash flow at 6.3% a year, so the market is asking for 6.3 percentage points above its own delivered rate. On that basis ELV looks priced above what its own growth record supports.
- Implied FCF growth
- 12.7%
- Historical FCF CAGR
- 6.3%
- Growth gap
- +6.3 pts
- Verdict
- RICH
- Discount rate (WACC)
- 6.83%
- Beta
- 0.54
Behaviour On Record
What ELV's own history says about today's numbers
- Realized volatility (21d)
- 21.2% 30th pct
- Below its peak
- -26.8%
- vs 200-day average
- +12.7%
- Up days (1y)
- 49%
Elevance Health, Inc. is currently running 21.2% annualised volatility over the last 21 sessions. Measured against ELV's own 13 years of daily returns rather than a market-wide average, that is the 30th percentile — on the quiet side for this stock, against a typical reading of 24.8%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
ELV is trading -26.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -18.8%, and the deepest was -43.3% in 2020. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits +12.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 72nd percentile — a somewhat wider gap than its own norm. Over the past year ELV closed higher on 49% of sessions, and it is currently 1 session into a rising streak.
On October specifically: over 13 years of records, ELV finished the month higher 8 of 13 times, with a median return of +1.0% and an average of +2.7%. Its strongest month historically has been November at +5.6% on average, its weakest July at -2.0%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: ELV has opened more than 2% away from the prior close in 101 of 3,266 sessions (3.1% of the time), with the largest gaps running +7.0% and -10.8%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, ELV moved an average of 3.5% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.8% and a largest of +5.5%.
All figures computed from 3,267 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against ELV's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of ELV's sector?
Elevance Health, Inc. sits in the Health Care sector, currently ranked 5th of 12 GICS sectors by relative-strength rotation score (improving).
- Sector rank
- #5 of 12
- Sector state
- Improving
- Sector rotation score
- 64
Analyst Rating Changes
Are analysts turning bullish or bearish on ELV?
Guggenheim most recently reiterated its rating on Elevance Health, Inc. to Buy on Oct 12, 2026 with a price target of $460 (from $455). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Guggenheim — Buy
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
Peers & ETF holders
ELV peers & ETF holders
Healthcare PlansMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Vanguard Group Inc | ▲ Buy | 23,019,518 | 10.87% | $8.07B | 2026-01-29 |
| BlackRock, Inc. | ▼ Sell | 18,991,090 | 8.97% | $7.34B | 2026-08-07 |
| Wellington Management Group LLP | ▲ Buy | 9,213,513 | 4.35% | $3.56B | 2026-08-14 |
| Geode Capital Management, LLC | ▼ Sell | 5,166,124 | 2.44% | $1.99B | 2026-08-12 |
| Harris Associates L P | ▲ Buy | 4,924,511 | 2.33% | $1.90B | 2026-08-14 |
| Artisan Partners Limited Partnership | ▼ Sell | 4,581,222 | 2.16% | $1.77B | 2026-08-13 |
| Invesco Ltd. | ▼ Sell | 4,234,231 | 2.00% | $1.64B | 2026-08-14 |
| Norges Bank | ▲ Buy | 3,958,856 | 1.87% | $1.53B | 2026-08-12 |
| FMR LLC (Fidelity) | ▲ Buy | 3,131,652 | 1.48% | $1.21B | 2026-08-13 |
| Morgan Stanley | ▼ Sell | 2,605,764 | 1.23% | $1.01B | 2026-08-13 |
| Northern Trust Corp | ▼ Sell | 2,114,986 | 1.00% | $817.93M | 2026-08-13 |
| Citigroup Inc | ▲ Buy | 2,096,863 | 0.99% | $810.92M | 2026-08-03 |
| Goldman Sachs Group Inc | ▲ Buy | 2,005,613 | 0.95% | $775.63M | 2026-08-14 |
| Bank of America Corp | ▼ Sell | 1,806,267 | 0.85% | $698.54M | 2026-08-14 |
| Baillie Gifford & Co | ▼ Sell | 1,083,237 | 0.51% | $418.92M | 2026-08-06 |
| JPMorgan Chase & Co | ▼ Sell | 997,214 | 0.47% | $386.95M | 2026-08-12 |
| Ruane, Cunniff & Goldfarb L.P. | ▼ Sell | 979,598 | 0.46% | $378.84M | 2026-08-14 |
| Citadel Advisors LLC | ▼ Sell | 906,386 | 0.43% | $350.53M | 2026-09-02 |
| Millennium Management LLC | ▼ Sell | 727,561 | 0.34% | $281.37M | 2026-08-14 |
| AllianceBernstein L.P. | ▼ Sell | 654,249 | 0.31% | $191.53M | 2026-08-14 |
| AQR Capital Management LLC | ▲ Buy | 426,160 | 0.20% | $164.41M | 2026-08-14 |
| Janus Henderson Group plc | ▲ Buy | 413,349 | 0.20% | $121.02M | 2026-05-18 |
| Wells Fargo & Company | ▼ Sell | 302,259 | 0.14% | $116.89M | 2026-08-14 |
| Renaissance Technologies LLC | ▲ Buy | 201,373 | 0.10% | $77.88M | 2026-08-13 |
| Adage Capital Partners GP, L.L.C. | ▲ Buy | 170,687 | 0.08% | $66.01M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-27 | 2026-07-21 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-08-13 | 2025-09-12 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-08-05 | 2025-09-12 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2025-07-10 | 2025-08-13 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2025-06-24 | 2025-08-13 |
| Gilbert Cisneros | House | CA31 | ▼ Sell | $1K - $15K | 2025-05-30 | 2025-06-06 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $15K - $50K | 2025-05-15 | 2025-05-31 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-05-12 | 2025-06-22 |
| Gilbert Cisneros | House | CA31 | ▲ Buy | $1K - $15K | 2025-04-29 | 2025-05-06 |
| Dan Newhouse | House | WA04 | ▼ Sell | $1K - $15K | 2025-04-11 | 2025-05-16 |
| Jared Moskowitz | House | FL23 | ▼ Sell | $1K - $15K | 2025-03-10 | 2025-04-08 |
| Jefferson Shreve | House | IN06 | ▲ Buy | $15K - $50K | 2025-02-24 | 2025-03-09 |
| Rob Bresnahan | House | PA08 | ▼ Sell | $1K - $15K | 2025-01-13 | 2025-02-13 |
| Valerie Hoyle | House | OR04 | ▲ Buy | $1K - $15K | 2024-10-29 | 2025-09-12 |